Article Sidebar

PDF
Issue: Vol. 563 No. 3 (2026)
Section: Các bài báo
DOI: 10.51298/vmj.v563i3.19148
Date Published: 08/10/2026
Views 0
Downloads 0
How to Cite
Giáp, V. V., Lưu, T. H., Bùi, Q. B., Nguyễn, A. T., Hoàng, Đ. C., Nguyễn, X. K., Tô, Q. D., Vi, T. D., & Nguyễn, Đ. C. (2026). PRELIMINARY RESULTS OF STEREOTACTIC BODY RADIATION THERAPY FOR EARLY-STAGE NON-SMALL CELL LUNG CANCER PATIENTS AT 108 MILITARY CENTRAL HOSPITAL. Vietnam Medical Journal, 563(3). https://doi.org/10.51298/vmj.v563i3.19148

PRELIMINARY RESULTS OF STEREOTACTIC BODY RADIATION THERAPY FOR EARLY-STAGE NON-SMALL CELL LUNG CANCER PATIENTS AT 108 MILITARY CENTRAL HOSPITAL

Văn Vũ Giáp1,2, , Thị Huyền Lưu1, Quang Biểu Bùi3, Anh Tuấn Nguyễn3, Đào Chinh Hoàng3, Xuân Kiên Nguyễn3, Quang Duy Tô3, Trần Doanh Vi4, Đình Châu Nguyễn3
1 Trường Đại học Y Dược – Đại học Thái Nguyên
2 Bệnh viện Ung Bướu Bắc Ninh
3 Bệnh viện Trung ương Quân đội 108
4 Bệnh viện Trung ương Thái Nguyên

Main Article Content

Abstract

Objective: To evaluate treatment response and acute side effects of stereotactic body radiation therapy (SBRT) in patients with early-stage non-small cell lung cancer (NSCLC).


Patients and Methods: A descriptive study combining retrospective and prospective data included 40 patients with stage I-IIA NSCLC (T1 - 2N0M0) treated with SBRT between January 2018 and February 2026. Tumor response was assessed according to RECIST version 1.1, and post-treatment chest computed tomography changes were evaluated at 3 and 6 months. Adverse events were recorded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.


Results: The mean age was 71.5 ± 10.2 years, 70.0% of the patients were male, and adenocarcinoma accounted for 95.0% of cases. The proportions of patients with stage IA, IB and IIA disease were 77.5%, 15.0% and 7.5%, respectively. The mean tumor diameter was 2.57 ± 0.9 cm (1.2 - 4.8 cm). The mean biologically effective dose was 109.19 ± 14.47 Gy. The objective response rates at 3 and 6 months were 52.5% and 87.5%, respectively. Chest CT changes at 3 and 6 months included focal consolidation (70.0% and 60.0%), diffuse consolidation (7.5% and 7.5%), focal ground-glass opacity (12.5% and 10.0%), diffuse ground-glass opacity (5.0% and 2.5%), and mixed patterns (5.0% and 20.0%), respectively. Grade 1-2 adverse events occurred in 47.5% of patients, including radiation pneumonitis in 35.0% and fatigue in 12.5%. No grade ≥3 adverse events were observed.


Conclusion: SBRT provides favorable early radiological responses with an acceptable toxicity profile in patients with early-stage non-small cell lung cancer who are medically inoperable.

Keywords

Non-small cell lung cancer, stereotactic body radiation therapy, treatment response, early adverse events

Article Details

References

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clinicians. 2024;74(3):229-263. doi:10.3322/caac.21834
2. Zarogoulidis K, Zarogoulidis P, Darwiche K, et al. Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis. 2013;5(Suppl 4):S389-S396. doi:10.3978/j.issn.2072-1439.2013.07.10
3. Zheng X, Schipper M, Kidwell K, et al. Survival Outcome After Stereotactic Body Radiation Therapy and Surgery for Stage I Non-Small Cell Lung Cancer: A Meta-Analysis. International Journal of Radiation Oncology*Biology*Physics. 2014;90(3):603-611. doi:10.1016/j.ijrobp.2014.05.055
4. Zer A, Ahn MJ, Barlesi F, et al. Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2025;36(11):1245-1262. doi:10.1016/j.annonc.2025.08.003
5. Videtic GMM, Hu C, Singh AK, et al. A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927). International Journal of Radiation Oncology*Biology*Physics. 2015;93(4):757-764. doi:10.1016/j.ijrobp.2015.07.2260
6. Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. The Lancet Oncology. 2015;16(6):630-637. doi:10.1016/S1470-2045(15)70168-3
7. De Bruycker A, Schneiders F, Gulstene S, et al. Evaluation of chest CT-scans following lung stereotactic ablative radiotherapy: Challenges and new insights. Lung Cancer. 2024;193:107848. doi:10.1016/j.lungcan.2024.107848
8. Timmerman R. Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer. JAMA. 2010;303(11):1070. doi:10.1001/jama.2010.261
9. Nagata Y, Hiraoka M, Shibata T, et al. Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403. International Journal of Radiation Oncology*Biology*Physics. 2015;93(5):989-996. doi:10.1016/j.ijrobp.2015.07.2278
10. Baumann P, Nyman J, Hoyer M, et al. Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non–Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy. JCO. 2009;27(20):3290-3296. doi:10.1200/JCO.2008.21.5681
11. Videtic GMM, Donington J, Giuliani M, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Practical Radiation Oncology. 2017;7(5):295-301. doi:10.1016/j.prro.2017.04.014